Mérieux Y, Debost M, Bernaud J, Raffin A, Meyer F, Rigal D
Pathol Biol (Paris). 1997 Nov;45(9):697-700.
To prevent human platelet alloimmunization, Blood Transfusion Centres have to develop a strategy close to the erythrocytes' one. The first step of this strategy is to perform the HPA typing of donors with an accurate method. We applied the PCR-SSP to type 800 platelet donors in the HPA-1 and HPA-5 systems and 350 in the HPA-2 and HPA-3 ones. This study reports the human platelet antigen frequencies of four platelet-specific alloantigen systems in the French population. The results are quite similar to those currently published for Caucasian population frequencies. Low prevalences are observed for the HPA-1b, (2%), HPA-2b (0.6%) and HPA-5b (2%) groups. Furthermore, this study confirms the need to type donors and recipients in the HPA-1 system at least, in case of post-transfusion pupura and platelet refractoriness to platelet transfusion therapy.
为预防人类血小板同种免疫，输血中心必须制定一套与红细胞检测策略相近的策略。该策略的第一步是采用精确方法对献血者进行人类血小板抗原（HPA）分型。我们应用聚合酶链反应-序列特异性引物（PCR-SSP）技术对800名血小板献血者进行HPA-1和HPA-5系统分型，对350名献血者进行HPA-2和HPA-3系统分型。本研究报告了法国人群中四种血小板特异性同种抗原系统的人类血小板抗原频率。结果与目前发表的高加索人群频率相当相似。观察到HPA-1b（2%）、HPA-2b（0.6%）和HPA-5b（2%）组的发生率较低。此外，本研究证实，至少在发生输血后紫癜和血小板输注治疗无效的情况下，有必要对献血者和受血者进行HPA-1系统分型。
